TABLE 3.
The top 10 productive journals in BRAF and MEK inhibitor resistance research in melanoma.
| Rank | Journal | Article counts | Percentage (3,503) | If | Quartile in category |
|---|---|---|---|---|---|
| 1 | Cancers | 145 | 4.14% | 4.5 | Q1 |
| 2 | Clinical cancer research | 121 | 3.45% | 10.0 | Q1 |
| 3 | Oncotarget | 112 | 3.20% | — | — |
| 4 | International journal of molecular sciences | 101 | 2.88% | 4.9 | Q1 |
| 5 | Cancer research | 96 | 2.74% | 12.5 | Q1 |
| 6 | Molecular cancer therapeutics | 79 | 2.26% | 5.3 | Q1 |
| 7 | Oncogene | 78 | 2.23% | 6.9 | Q1 |
| 8 | Pigment cell and melanoma research | 63 | 1.80% | 3.9 | Q1 |
| 9 | Cancer discovery | 60 | 1.71% | 29.7 | Q1 |
| 10 | Plos one | 54 | 1.54% | 2.9 | Q1 |